- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S3726
| Related Targets | PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX |
|---|---|
| Other Prostaglandin Receptor Inhibitors | PF-04418948 TG4-155 E7046 (ER-886406) Grapiprant (CJ-023,423) BI-671800 Setipiprant (ACT-129968) Terutroban Genz-123346 free base EP4-IN-1 Ozagrel |
|
In vitro |
DMSO
: 99 mg/mL
(199.34 mM)
Ethanol : 7 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 496.62 | Formula | C26H32N4O4S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 475086-01-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NS-304, ACT-293987 | Smiles | CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3 | ||
| Targets/IC50/Ki |
prostacyclin IP receptor
|
|---|---|
| In vitro |
Selexipag is an orally available, selective IP receptor agonist. It is rapidly hydrolysed in the hepatic microsomes to an active metabolite. This compound and its active metabolite have a higher binding affinity for the human IP receptor than for any other prostanoid receptor.
|
| In vivo |
As selexipag is rapidly hydrolysed in the liver to the active metabolite, peak-trough fluctuations in serum levels of active compound may be reduced, thereby reducing the likelihood of adverse events. Thus, this compound is well tolerated, with a safety profile in line with that of the expected pharmacological effect. It has a half-life of 0.8-2.5 hours.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.